| Glaucoma, Open-Angle
Durysta vs Rocklatan
Side-by-side clinical, coverage, and cost comparison for glaucoma, open-angle.Deep comparison between: Durysta vs Rocklatan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRocklatan has a higher rate of injection site reactions vs Durysta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rocklatan but not Durysta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Durysta
Rocklatan
At A Glance
Intracameral implant
Single dose
Prostaglandin analog
Ophthalmic
Once daily (evening)
Rho kinase inhibitor / prostaglandin F2alpha analogue
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension Single biodegradable intracameral implant (10 mcg bimatoprost) administered once into the anterior chamber under aseptic conditions; do not readminister to a previously treated eye.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; do not exceed once daily. If used with other topical ophthalmic drugs, administer at least 5 minutes apart.
Contraindications
- Active or suspected ocular or periocular infections
- Corneal endothelial cell dystrophy (e.g., Fuchs' Dystrophy)
- Prior corneal transplantation or endothelial cell transplants (e.g., DSAEK)
- Absent or ruptured posterior lens capsule (risk of implant migration into the posterior segment)
- Hypersensitivity to bimatoprost or any other component of the product
—
Adverse Reactions
Most common (>=5%) Conjunctival hyperemia (27%), foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, increased IOP, corneal endothelial cell loss, blurred vision, iritis, headache
Serious Implant migration, hypersensitivity, corneal adverse reactions, macular edema, intraocular inflammation, pigmentation, endophthalmitis
Postmarketing Endophthalmitis
Most common (>=11%) Conjunctival hyperemia, instillation site pain, corneal verticillata, conjunctival hemorrhage
Postmarketing Epithelial corneal edema in patients with pre-existing corneal stromal edema or ocular procedures affecting corneal endothelial function
Pharmacology
Bimatoprost is a prostaglandin analog with ocular hypotensive activity that lowers IOP by increasing aqueous humor outflow through both the trabecular meshwork (conventional) and uveoscleral (unconventional) routes.
Fixed-dose combination of netarsudil (Rho kinase inhibitor) and latanoprost (prostaglandin F2alpha analogue) that reduces elevated intraocular pressure by increasing the outflow of aqueous humor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Durysta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Rocklatan
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
UnitedHealthcare
Durysta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rocklatan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (4/8)
Humana
Durysta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Rocklatan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Durysta CoPay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rocklatan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DurystaView full Durysta profile
RocklatanView full Rocklatan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.